CorMedix (CRMD) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
CorMedix (CRMD) PT Lowered to $9 at RBC Capital
March 13, 2024 6:21 AM EDTRBC Capital analyst Gregory Renza lowered the price target on CorMedix (NASDAQ: CRMD) to $9.00 (from $10.00) while maintaining a Outperform rating.
The analyst comments "CRMD reported 4Q, with consistent messaging and incremental updates on launch & reimbursement strategy, into the reaffirmed proposed 4/15 inpatient launch, and... More
